Guard Therapeutics: Positive Results

Research Note

2020-07-08

13:25

Redeye reiterate our valuation on Guard Therapeutics (ticker: GUARD) following positive news. Today Guard Therapeutics presented follow-up data on its phase 1A, single ascending dose (SAD) study. The results are positive and somewhat unexpected.

NF

JS

Nima Faroghi

Jakob Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.